Skip to main content

Table 2 Randomized Trials for PCNSL

From: Current and emerging therapies for primary central nervous system lymphoma

  Year Diagnosis N Age
(y)
Regimens (Arms) Outcome
ORR/CR PFS OS
Induction 2000 [51] PCNSL 53 NA WBRT(40) WBRT(40)+CHOP 18% vs 46% NA NA
2009 [52] PCNSL, ND 79 18-70 MTX(3.5) MTX(3.5)+AraC(2) 40% vs 69% NA NA
2015 [53] PCNSL, ND 95 ≥60 MTX(3.5)+TMZ(150) MTX(3.5)+Pro(100)+V(1.4)+AraC(3) 71% vs 82% 6.1m vs 9.5m NA
2016 [54] PCNSL, ND 219 18-70 MTX(3.5)+AraC(2) MTX(3.5)+AraC(2)+R(375) MTX(3.5)+AraC(2)+R(375)+T(30) (MATRix) 53% vs 74% vs 87% 42% vs 56% vs 69% NA
2018 [55] PCNSL, ND 49 14-69 MTX(3.5)+ AraC(1.0) F(100)+Ten(60)+DXM(40) 40% vs 33% NA NA
2019 [56] PCNSL, ND 199 18-70 MTX(3.0)+BCNU(100)+Ten(100)+Pred(60) R(375, weekly)+MTX(3.0)+BCNU(100)+Ten(100)+Pred(60) 86% vs 86% (≤60 y) 26.3m vs 59.9m
(>60 y) 19.6m vs 14.6m
(≤60 y) 56.7m vs not reached
(>60 y) 49.2m vs 34.9m
Consolidation 2010 [57] PCNSL, ND 318 55-69 w/w WBRT(45) NA 11.9m vs 18.3m 37.1m vs 32.4m
2017 [58] PCNSL, ND 118 18-70 WBRT ASCT 95% vs 93% NA NA
2017 [59] PCNSL, ND 318 55-69 w/w WBRT(45) Reduced QoL and lower value of MMSE in WBRT arm
2019 [60] PCNSL, ND 140 18-60 WBRT ASCT NA 63% vs 87% Cognitive impairment after WBRT
  1. Abbreviations: A cytarabine (g/m2); BCNU carmustine (mg/m2); CHOP cyclophosphamide, doxorubicin, vincristine, prednisone;CR complete remission; DXM dexamethasone (mg); EFS event-free survival; I ifosfamide (g/m2); F fotemustine (mg/m2); M methotrexate (g/m2); MMSE Mini Mental State Examinations; NA not available; NCR no complete remission; ND newly diagnosed; ORR overall response rate; OS overall survival; PCNSL primary central nervous system lymphoma; PFS progression-free survival; PR partial remission; Pred prednisone (mg/m2); Pro procarbazine (mg/m2); QoL quality of life; R rituximab (mg/m2); T thiotepa (mg/m2); Ten teniposide (mg/m2); TMZ temozolomide (mg/m2); WBRT/RT whole brain radiotherapy (Gy); w/w wait and watch; V vincristine (mg/m2); VP16 etoposide (mg/m2)